Diabetic Nephropathy

Sotagliflozin Reduces Risk for Adverse CV Events in Diabetic Kidney Disease

Publish Date November 18, 2020

Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.

Nephropathy Progression in Type 1 Diabetes Linked to Depression

Publish Date November 18, 2020

Whether successful treatment of depression reduces the risk for progression needs to be determined.

Finerenone NDA Submitted for Diabetic Kidney Disease

Publish Date November 11, 2020

The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.

Highlights From the New KDIGO Guideline on Diabetes and CKD

Publish Date November 11, 2020

The new KDIGO guideline highlights specific management differences by CKD severity.

Patients With Diabetes and CVD on Empagliflozin Have Fewer CV, Renal Events

Publish Date November 5, 2020

Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.

Efficacy of Endothelin Receptor Antagonists for Renal Protection in Diabetic Kidney Disease

Publish Date November 4, 2020

Atrasentan outperformed both avosentan and bosentan for renoprotection in patients with type 2 diabetic kidney disease.

Updated ADA Guideline Recommends Combo Tx for Type 2 Diabetes With CKD

Publish Date September 2, 2020

The 2020 ADA guideline update reflects evidence from recent major trials with cardiovascular and renal outcomes.

Dapagliflozin Reduces Kidney Failure Risk, Prolongs Survival in CKD

Publish Date September 1, 2020

Dapagliflozin appears to preserve kidney function and improve survival in patients with chronic kidney disease whether or not they have type 2 diabetes.

Empagliflozin Beneficial in Heart Failure With Reduced Ejection Fraction

Publish Date August 31, 2020

In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction.

Boxed Warning Removed From Canagliflozin Labeling

Publish Date August 28, 2020

The FDA concluded “the risk no longer meets the standard for a Boxed Warning.”